Lucid Diagnostics Inc. (LUCD) Stock Price & Analysis
Lucid Diagnostics Inc. (LUCD) — MoonshotScore 16/100 (Weak band), calculated Nov 22, 2026. Price $0.3727 (-3.52%), as of the Nov 20, 2026 trading session; market cap $72.6M.
Educational signal · not a buy or sell recommendation · How to read this
Lucid Diagnostics Inc. · LUCD · NASDAQ
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux disease. The company's lead products, EsoGuard and EsoCheck, are designed for the early detection of esophageal precancer and cancer.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Lucid Diagnostics (LUCD)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and weak growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.
- quarterly revenue $1M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z -19.43 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 16 | Weak | |
| 15 | Weak | |
| 15 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak |
The score was 16 in the stored Nov 21, 2026 snapshot and remains 16 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3727 | |
| Change on the day | -3.52% | |
| 52-week range | $0.303 – $1.63 | |
| Market capitalisation | $72.6M | |
| Shares traded on the day | 2.26M |
Price & events
Other perspectives
Council score for Lucid Diagnostics (LUCD): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 22, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Lucid Diagnostics (LUCD), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lucid Diagnostics Inc. (LUCD) is listed on NASDAQ. It employs 82 people and is led by Lishan Aklog. In Q3 FY2025 it reported revenue of $1M and net income of -$10M. The market values it at $72.6M.
What do the latest results show for Lucid Diagnostics (LUCD)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $1M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $1M | -$10M | -$0.10 (diluted) |
| Q4 FY2025 | $2M | -$16M | -$0.10 (diluted) |
| Q1 FY2026 | $1M | -$14M | -$0.17 (diluted) |
| Q2 FY2026 | $1M | -$12M | -$0.08 (diluted) |
What are the financial strengths and risks for Lucid Diagnostics (LUCD)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -19.43 · Piotroski F 2. Trailing ratios: ROA -79.0% · current ratio 1.20.
Data-derived red flags
- Listing risk — at $0.3727 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -19.43 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Lucid Diagnostics (LUCD)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q3 FY2025) was filed Nov 12, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Lucid Diagnostics compare with its peers?
Short answer
Lucid Diagnostics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $22.98 Nov 20, 2026 | $188M | 88 5-pillar Nov 22, 2026 | |
| $8.52 Nov 20, 2026 | $323M | 88 5-pillar Nov 22, 2026 | |
| $8.48 Nov 20, 2026 | $333M | 86 5-pillar Nov 22, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 72 5-pillar Nov 22, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 22, 2026 | |
| $4.46 Nov 20, 2026 | $54.8M | 43 5-pillar Nov 22, 2026 | |
| $2.93 Nov 20, 2026 | $87.6M | 41 5-pillar Nov 22, 2026 | |
| $2.08 Nov 20, 2026 | $31.5M | 38 5-pillar Nov 22, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 22, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 22, 2026 | |
| $8.67 Nov 20, 2026 | $361M | 35 5-pillar Nov 22, 2026 | |
| $10.18 Nov 20, 2026 | $566M | 34 5-pillar Nov 22, 2026 | |
| Lucid Diagnostics (LUCD) — this page | $0.3727 | $72.6M | 16 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $2.00 – $2.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $2.00
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $2.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LUCD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LUCD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Lucid Diagnostics (LUCD)?
Common Questions About LUCD
These answers are editorial: 1 of these 9 answers is drawn from the LUCD research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LUCD?
LUCD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux disease.
Is LUCD a good stock to buy?
Stock Expert AI does not rate LUCD buy, sell or hold. Lucid Diagnostics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LUCD stock price today?
The last price recorded for Lucid Diagnostics Inc. (LUCD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LUCD price target?
The last analyst consensus price target we captured for Lucid Diagnostics Inc. (LUCD), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the key growth opportunities for LUCD in healthcare?
Lucid Diagnostics Inc. has several key growth opportunities within the healthcare sector. A primary driver is the expansion of adoption for its EsoGuard and EsoCheck products among the large population of GERD patients at risk for esophageal precancer.
What are the key factors to evaluate for LUCD?
Lucid Diagnostics Inc. (LUCD) holds a MoonshotScore in the low range. Not financial advice.
How frequently does LUCD data refresh on this page?
LUCD's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LUCD's recent stock price performance?
Lucid Diagnostics Inc. (LUCD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercial-stage company with active product offerings (EsoGuard and EsoCheck). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LUCD overvalued or undervalued right now?
Lucid Diagnostics Inc. (LUCD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 12 from Financial Modeling Prep (FMP), 5 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com